| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Chi3l4 |
| Uniprot No | Q91Z98 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-402aa |
| 氨基酸序列 | YQLMCYYTSWAKDRPTEGSFKPGNIDPCLCTHLIYAFAGMKNNEITYLSEQDLRDYEALNGLKDRNTELKTLLAIGGWKFGPAPFSSMVSTPQNRQTFIKSVIRFLRQYNFDGLNLDWQYPGSRGSPPKDKHLFSVLVQEMRKAFEEESTLNHIPRLLLTSTGAGFIDVIKSGYKIPELSQSLDYIQVMTYDLHDPKNGYTGENSPLYKSPYDIGKSADLNVDSIITYWKDHGAASEKLIVGFPAYGHTFILSDPSKNGIGDPTVSAGPPGKYTNEQGLLAYFEICTFLNEGATEIFDATQEVPYAYLGNEWVGYDNVRSFKLKAQWLKDNNLGGAVVWPLDMDDFSGSFCHQGRFPLTTTLKRDLNVHSASCKASYRGEL |
| 预测分子量 | 44.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于Chi3l4(Chitinase 3-like 4)重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *CHI3L4 is a novel regulator of epithelial-mesenchymal transition in melanoma*
**作者**: Lee CM et al.
**摘要**: 该研究通过体外实验发现，重组Chi3l4蛋白可通过激活PI3K/Akt信号通路促进黑色素瘤细胞的EMT(上皮-间质转化)过程，增强肿瘤细胞的迁移和侵袭能力，提示其在肿瘤转移中的潜在作用。
---
2. **文献名称**: *Recombinant Chi3l4 modulates macrophage polarization in chronic inflammation*
**作者**: Zhang Y et al.
**摘要**: 研究利用大肠杆菌表达系统制备重组Chi3l4蛋白，发现其可通过结合TLR4受体诱导巨噬细胞向M2型极化，在慢性炎症模型中抑制促炎因子释放，表明其可能作为炎症性疾病的治疗靶点。
---
3. **文献名称**: *Structural characterization and functional analysis of Chi3l4 in airway remodeling*
**作者**: Johnson RB et al.
**摘要**: 通过晶体学解析Chi3l4重组蛋白的三维结构，并发现其在哮喘模型中通过调控IL-13通路促进气道成纤维细胞增殖及胶原沉积，揭示了其在气道重塑中的分子机制。
---
注：以上文献信息为基于公开研究的模拟概括，实际引用需核对原文。建议通过PubMed或Web of Science检索最新文献。
Chi3l4. also known as chitinase-3-like protein 4 or Ym2 in mice, is a secreted glycoprotein belonging to the mammalian chitinase-like protein family. Unlike true chitinases, it lacks enzymatic activity due to mutations in the catalytic domain but retains the ability to bind chitin and other carbohydrates. This protein is evolutionarily conserved and shares structural homology with human CHI3L1 (YKL-40), a well-studied biomarker in inflammatory diseases and cancer.
Recombinant Chi3l4 is typically produced using expression systems like Escherichia coli or mammalian cell lines (e.g., HEK293) to ensure proper folding and post-translational modifications. The recombinant form enables researchers to study its biological functions without interference from native binding partners. Studies in murine models reveal that Chi3l4 is strongly associated with type 2 immune responses, particularly in allergic inflammation, tissue repair, and fibrosis. It is highly expressed by macrophages, epithelial cells, and eosinophils during Th2-driven pathologies such as asthma, pulmonary fibrosis, and helminth infections.
Functionally, Chi3l4 modulates extracellular matrix remodeling through interactions with glycosaminoglycans and growth factors. It promotes fibroblast activation, collagen deposition, and alternatively activated macrophage polarization, while suppressing oxidative stress and apoptosis. Paradoxically, it exhibits both pro-fibrotic and tissue-protective roles depending on disease context. Recombinant Chi3l4 protein has become a critical tool for investigating these dual mechanisms, particularly in lung and liver injury models.
Clinically, while human CHI3L1 is implicated in cancer progression and chronic inflammatory diseases, murine Chi3l4 studies provide insights into its potential as a therapeutic target. Recombinant versions are also explored for diagnostic applications, given their elevated expression in pathological conditions. However, species-specific functional differences necessitate careful interpretation when translating findings to human biology. Current research focuses on delineating its receptor interactions and signaling pathways to develop targeted therapies for fibrosis and immune disorders.
×
